SequelSEC

CORCEPT THERAPEUTICS INC CORT

Pharmaceutical Preparations · CIK 0001088856 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$830.81M
Fiscal year ended 2026-06-30
Operating income
$6.40M
Fiscal year ended 2026-06-30
Free cash flow
$106.92M
Fiscal year ended 2026-06-30

CORCEPT THERAPEUTICS INC (CORT) reported revenue of $830.81M and net income of $55.18M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from CORCEPT THERAPEUTICS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

CORCEPT THERAPEUTICS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$830.81M
Cost of revenue$14.08M
Gross profit$816.73M
Operating income$6.40M
Net income$55.18M
Research & development$253.86M
Weighted-average diluted sharesUnavailable
Pretax income$26.37M
Income tax expense-$28.81M
Diluted EPS$0.42
Selling, general & administrative$556.47M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

CORCEPT THERAPEUTICS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$111.04M
Total assets$888.70M
Current assets$439.68M
Total liabilities$182.93M
Current liabilities$153.80M
Total equity incl. NCI$705.78M
Temporary (mezzanine) equityUnavailable
Inventory$13.18M
Accounts receivable$76.92M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$14.91M

Cash flow

CORCEPT THERAPEUTICS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$109.70M
Capital expenditures$2.78M
Investing cash flow-$21.90M
Financing cash flow-$78.91M
Net change in cash$8.29M
Stock-based compensation$96.11M
Common dividends paidUnavailable
Common share repurchases$42.46M
Depreciation & amortization$1.68M

Derived

CORCEPT THERAPEUTICS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$106.92M
Gross margin98.3%
Operating margin0.8%
FCF margin12.9%
SBC / revenue11.6%
Current ratio2.86x
Revenue YoY growth16.0%
Net margin6.6%
R&D / revenue30.6%
CapEx / revenue0.3%
Long-term debt / equityUnavailable
Effective tax rate-109.3%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CORT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-29View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.